Search

for
Search:

Sort by

Research

480-510 / 1000+ results

Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis

research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis

November 2023 in “Indian Dermatology Online Journal”

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

research N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase

17 citations , December 2004 in “Bioorganic & Medicinal Chemistry Letters”

Scientists found new, better-working inhibitors for a hormone-related enzyme.

research Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity

13 citations , October 2017 in “Bioorganic & Medicinal Chemistry”

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

research Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms

1 citations , March 2021 in “Phytomedicine plus”

Cernitin™, a pollen extract, was found to significantly reduce pain and inflammation in rats with chronic prostatitis, suggesting it could be a useful alternative to certain anti-inflammatory drugs.

research Tofacitinib therapy for children with severe alopecia areata

39 citations , January 2019 in “Journal of the American Academy of Dermatology”

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome

July 2024 in “Journal of Investigative Dermatology”

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

research Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo

March 2026 in “Clinical Cosmetic and Investigational Dermatology”

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

research Enzyme Inhibitors from Gorgonians and Soft Corals

4 citations , January 2023 in “Marine Drugs”

Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.

research 1492 Prostacyclin pathway to enhance wound healing in diabetic foot ulcers

April 2023 in “Journal of Investigative Dermatology”

Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.

research Cutaneous manifestations associated with immune checkpoint inhibitors

14 citations , February 2023 in “Frontiers in immunology”

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.

research BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege

July 2022 in “British Journal of Dermatology”

research Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

3 citations , November 1998 in “PubMed”

research Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

January 2022 in “SSRN Electronic Journal”

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome

1 citations , July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology”

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

research Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract

15 citations , December 2020 in “Pharmacology Research & Perspectives”

Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients

24 citations , January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

research Advancing Design Strategy of PROTACs for Cancer Therapy

4 citations , June 2025 in “MedComm”

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

research Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman.

April 2010 in “PubMed”

A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.

research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

24 citations , July 2021 in “Pharmaceutics”

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

The Use of Tofacitinib in the Treatment of Immune-Mediated Universal Alopecia in a Patient with Systemic Lupus Erythematosus: A Case Report

research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT

January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020”

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

research Peripheral neuropathy associated with tofacitinib use in alopecia universalis

1 citations , August 2022 in “Journal of Dermatology and Dermatologic Surgery”

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control

research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control

March 2026 in “Clinical Cosmetic and Investigational Dermatology”

Upadacitinib improved multiple immune-related conditions in one patient.

research Prevention of erlotinib-induced folliculitis with doxycycline

3 citations , September 2016 in “Dermatologic Therapy”

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Topical Application of Aprepitant Inhibits Erlotinib-Induced Facial Dermatitis and Hair Loss

research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss

January 2024 in “Journal of dermatology and skin science”

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

research JAK inhibition in the treatment of alopecia areata – a promising new dawn?

29 citations , December 2019 in “Expert review of clinical pharmacology”

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

research Oral tofacitinib for the treatment of alopecia areata in pediatric patients

13 citations , November 2021 in “Pediatric Dermatology”

Tofacitinib taken by mouth helps treat hair loss in children.

research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana

January 2008 in “Projeto: revista mensal de arquitetura”

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis

April 2026 in “Clinical Journal of Gastroenterology”

A woman in her 40s with ulcerative colitis experienced suspected drug hypersensitivity to upadacitinib, which mimicked disease exacerbation. Despite treatment with upadacitinib, her symptoms worsened, and a drug-induced lymphocyte stimulation test showed a 230% stimulation index for upadacitinib. After discontinuing upadacitinib and starting tacrolimus, she achieved rapid remission. This case highlights that drug hypersensitivity to Janus kinase inhibitors like upadacitinib should be considered when clinical deterioration occurs during therapy for ulcerative colitis.

12-O-Tetradecanoylphorbol-13-Acetate Induces Apoptosis in Renal Epithelial Cells Through a Growth Signal Conflict Prevented by Activated Ras

research 12-O-Tetradecanoylphorbol-13-acetate Induces Apoptosis in Renal Epithelial Cells through a Growth Signal Conflict Which Is Prevented by Activated ras1

4 citations , January 2001 in “Archives of Biochemistry and Biophysics”

Activated ras can protect kidney cells from a certain substance that causes cell death.

research Inhibition of Wnt/β‐catenin pathway promotes regenerative repair of cutaneous and cartilage injury

41 citations , August 2015 in “The FASEB Journal”

Blocking the Wnt/β‐catenin pathway can speed up wound healing, reduce scarring, and improve cartilage repair.

← Previous page Next page →